Simvastatin Treatment for Duchenne Muscular Dystrophy Muscle Strength

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Duchenne muscular dystrophy, such as steroids, have limited effectiveness in slowing disease progression and are associated with significant side effects, while statins, typically used to treat ischemic muscle diseases, are contraindicated due to concerns about statin-induced myopathies.

Innovation Solution

Administering a therapeutically effective amount of a lipophilic statin drug, such as simvastatin, to treat neuromuscular diseases like Duchenne muscular dystrophy, using formulations like liquid, dissolvable tablets, or films to bypass swallowing issues and potentially combine with other therapeutic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If steroids are used to treat Duchenne muscular dystrophy, then muscle strength is temporarily maintained, but significant side effects occur and disease progression is not effectively slowed

Engineering Contradiction:

Improvemuscle strengthVSAvoidside effects

Core Design Contradiction:

StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using statins, drugs traditionally known to cause muscle damage (harmful), and converting them into a beneficial treatment for Duchenne muscular dystrophy. The statin-induced muscle stress activates protective cellular pathways (autophagy and heat shock response) that ultimately strengthen dystrophic muscle, transforming the drug's harmful potential into therapeutic benefit

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the therapeutic parameter from conventional muscle-strengthening agents to statins, which operate through a different mechanism. By altering the biochemical parameter (inhibiting HMG-CoA reductase and modulating cholesterol metabolism), the treatment achieves muscle protection through cellular stress adaptation rather than direct anabolic effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If statins are avoided in Duchenne muscular dystrophy, then statin-induced myopathy risk is eliminated, but a potentially effective treatment is denied to patients

Engineering Contradiction:

ImprovesafetyVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by differentiating between healthy muscle and dystrophic muscle responses to statins. In dystrophic muscle, statins activate protective pathways without causing the myopathy seen in healthy muscle, allowing localized therapeutic benefit while avoiding systemic harm

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent inverts the conventional wisdom by using a drug class (statins) traditionally contraindicated in muscle diseases as the treatment of choice for Duchenne muscular dystrophy. This inversion challenges the assumption that all muscle-damaging drugs are harmful in muscular dystrophy

Inventive Principle:

Principle #13The other way round (Inversion)

3Stability of the object's composition

If conventional treatments are used, then current standard of care is maintained, but effectiveness in slowing disease progression is limited

Engineering Contradiction:

Improvecurrent treatment protocolVSAvoiddisease progression rate

Core Design Contradiction:

Stability of the object's compositionVSProductivity

Solution Approach 1:

The patent applies preliminary action by activating cellular protective pathways (autophagy and heat shock response) before significant muscle degradation occurs. Statins preemptively strengthen muscle cells through stress adaptation, preventing rather than merely treating damage

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS9974767B2Statins in the treatment of muscular dystrophies and myopathies

Publication Date: 2018.05.22 UNIV OF WASHINGTON

AI summary

The invention provides methods and compositions for treating neuromuscular diseases including, but not limited to muscular dystrophies. It is demonstrated herein that statin drugs are therapeutic for neuromuscular disease, including, but not limited to muscular dystrophies.